INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
NASDAQ · Instruments & Medical Devices · Surgical & Medical Instruments & Apparatus
- Price
- $15.53
- Day
- -3.06%
- Market cap
- $1.21B
Close 2026-09-23.
The company
OVERVIEW Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat (“ENT”). We are the world leader in neurosurgery and one of the top three providers in the U.S. in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about 30% of our overall revenue and focuses on wound reconstruction and care and private label.
From Item 1: OVERVIEW.
By business segment
- Codman Specialty Surgical — 73%
- Tissue Technologies — 27%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- Rubric Capital Management LP — $139.26M
- BlackRock, Inc. — $135.02M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $67.23M
- FULLER & THALER ASSET MANAGEMENT, INC. — $61.71M
- Invesco Ltd. — $60.87M
- STATE STREET CORP — $52.93M
- VANGUARD CAPITAL MANAGEMENT LLC — $52.91M
- PARADIGM CAPITAL MANAGEMENT INC/NY — $51.71M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- GRAVES JEFFREY A (Director) bought 9,000 shares at $11.35 on 2025-11-05
- Schwartz Eric (EVP, Chief Legal Officer & Sec) sold 4,070 shares at $24.60 on 2024-12-03
- McBreen Michael J. (EVP & President, CSS) sold 1,700 shares at $24.16 on 2024-12-02
- Mosebrook Jeffrey (SVP, Fin & Princ Acct Officer) sold 1,191 shares at $21.58 on 2024-08-19
Recent filings
- 8-K — 2026-09-08
- 4 — 2026-09-04
- SCHEDULE 13G/A — 2026-08-13
- SCHEDULE 13G — 2026-07-31
- 10-Q — 2026-07-29
- 8-K — 2026-07-29
- 4 — 2026-07-06
- 4 — 2026-07-06
- 4 — 2026-07-06
- 4 — 2026-07-06